NCT04624490View on ClinicalTrials.gov

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

PHASE1RecruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

October 26, 2025

Study Completion Date

October 26, 2026

Conditions

AsthmaCOPDInterstitial Lung DiseaseCystic FibrosisPulmonary HypertensionPulmonary InfectionOther Lung Disease

Interventions

DRUG

Hyperpolarized Xe129

During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.

Trial Locations (1)

66160

RECRUITING

University of Kansas Medical Center, Kansas City

All Listed Sponsors

lead

Mario Castro, MD, MPH

OTHER

NCT04624490 - Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease | Biotech Hunter | Biotech Hunter